Advertisement

Index by author

February 01, 2019; Volume 47,Issue 2

A

  1. Anitha, Mallappa

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

B

  1. Badée, Justine

    1. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
      Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt and Stephen Fowler
      Drug Metabolism and Disposition February 2019, 47 (2) 124-134; DOI: https://doi.org/10.1124/dmd.118.084301

  2. Beaudoin, James J.

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

  3. Bezençon, Jacqueline

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

  4. Bibikova, Elena

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

  5. Brock, William J.

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

  6. Bromek, Ewa

    1. Serotonin Receptors of 5-HT2 Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone–Releasing Hormone/Growth Hormone Hormonal Pathway
      Ewa Bromek, Marta Rysz, Anna Haduch and Władysława A. Daniel
      Drug Metabolism and Disposition February 2019, 47 (2) 80-85; DOI: https://doi.org/10.1124/dmd.118.083808

  7. Brouwer, Kim L. R.

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

C

  1. Cai, Jingwei

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

  2. Callaghan, Richard

    1. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
      Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells and Richard Callaghan
      Drug Metabolism and Disposition February 2019, 47 (2) 164-172; DOI: https://doi.org/10.1124/dmd.118.083188

  3. Cao, Yanguang

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

  4. Capuano, Ben

    1. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
      Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells and Richard Callaghan
      Drug Metabolism and Disposition February 2019, 47 (2) 164-172; DOI: https://doi.org/10.1124/dmd.118.083188

  5. Cardinal, Kristen

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

  6. Collier, Abby C.

    1. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
      Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt and Stephen Fowler
      Drug Metabolism and Disposition February 2019, 47 (2) 124-134; DOI: https://doi.org/10.1124/dmd.118.084301

D

  1. Daniel, Władysława A.

    1. Serotonin Receptors of 5-HT2 Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone–Releasing Hormone/Growth Hormone Hormonal Pathway
      Ewa Bromek, Marta Rysz, Anna Haduch and Władysława A. Daniel
      Drug Metabolism and Disposition February 2019, 47 (2) 80-85; DOI: https://doi.org/10.1124/dmd.118.083808

  2. DeBono, Aaron J.

    1. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
      Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells and Richard Callaghan
      Drug Metabolism and Disposition February 2019, 47 (2) 164-172; DOI: https://doi.org/10.1124/dmd.118.083188

E

  1. El-Kadi, Ayman O. S.

    1. Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity
      Sherif M. Shoieb, Ahmed A. El-Sherbeni and Ayman O. S. El-Kadi
      Drug Metabolism and Disposition February 2019, 47 (2) 67-70; DOI: https://doi.org/10.1124/dmd.118.084657

  2. El-Sherbeni, Ahmed A.

    1. Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity
      Sherif M. Shoieb, Ahmed A. El-Sherbeni and Ayman O. S. El-Kadi
      Drug Metabolism and Disposition February 2019, 47 (2) 67-70; DOI: https://doi.org/10.1124/dmd.118.084657

  3. Evarts, Jerry

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

F

  1. Fowler, Stephen

    1. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
      Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt and Stephen Fowler
      Drug Metabolism and Disposition February 2019, 47 (2) 124-134; DOI: https://doi.org/10.1124/dmd.118.084301

G

  1. Girardet, Jean-Luc

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

  2. Gohdes, Mark

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

  3. Gui, Wei

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

H

  1. Haduch, Anna

    1. Serotonin Receptors of 5-HT2 Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone–Releasing Hormone/Growth Hormone Hormonal Pathway
      Ewa Bromek, Marta Rysz, Anna Haduch and Władysława A. Daniel
      Drug Metabolism and Disposition February 2019, 47 (2) 80-85; DOI: https://doi.org/10.1124/dmd.118.083808

  2. Henshaw, Georgia K.

    1. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
      Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells and Richard Callaghan
      Drug Metabolism and Disposition February 2019, 47 (2) 164-172; DOI: https://doi.org/10.1124/dmd.118.083188

I

  1. Ingallinera, Tim

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

K

  1. Kim, Soo-Jin

    1. Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the “Albumin-Mediated” Hepatic Uptake Mechanism on the Basis of the “Facilitated-Dissociation Model”
      Soo-Jin Kim, Kyeong-Ryoon Lee, Seiji Miyauchi and Yuichi Sugiyama
      Drug Metabolism and Disposition February 2019, 47 (2) 94-103; DOI: https://doi.org/10.1124/dmd.118.083733

  2. Kojima, Koki

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

  3. Koo, Imhoi

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

L

  1. Lee, Caroline A.

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

  2. Lee, Kyeong-Ryoon

    1. Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the “Albumin-Mediated” Hepatic Uptake Mechanism on the Basis of the “Facilitated-Dissociation Model”
      Soo-Jin Kim, Kyeong-Ryoon Lee, Seiji Miyauchi and Yuichi Sugiyama
      Drug Metabolism and Disposition February 2019, 47 (2) 94-103; DOI: https://doi.org/10.1124/dmd.118.083733

  3. Levy, René H.

    1. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017
      Jingjing Yu, Ichiko D. Petrie, René H. Levy and Isabelle Ragueneau-Majlessi
      Drug Metabolism and Disposition February 2019, 47 (2) 135-144; DOI: https://doi.org/10.1124/dmd.118.084905

  4. Li, Yongmei

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  5. Liang, Chenmeizi

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  6. Liu, Mingyao

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  7. Lu, Jian

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

M

  1. Ma, Xinrun

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  2. Ma, Xueyun

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  3. Miner, Jeffrey N.

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

  4. Miyauchi, Seiji

    1. Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the “Albumin-Mediated” Hepatic Uptake Mechanism on the Basis of the “Facilitated-Dissociation Model”
      Soo-Jin Kim, Kyeong-Ryoon Lee, Seiji Miyauchi and Yuichi Sugiyama
      Drug Metabolism and Disposition February 2019, 47 (2) 94-103; DOI: https://doi.org/10.1124/dmd.118.083733

  5. Mizuno, Katsuhiko

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

  6. Muthiah, Divya

    1. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
      Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells and Richard Callaghan
      Drug Metabolism and Disposition February 2019, 47 (2) 164-172; DOI: https://doi.org/10.1124/dmd.118.083188

N

  1. Nakada, Tomohisa

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

  2. Nakamaru, Yoshinobu

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

  3. Nichols, Robert G.

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

O

  1. Ogasawara, Akihito

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

P

  1. Parrott, Neil

    1. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
      Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt and Stephen Fowler
      Drug Metabolism and Disposition February 2019, 47 (2) 124-134; DOI: https://doi.org/10.1124/dmd.118.084301

  2. Patterson, Andrew D.

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

  3. Pearson, Paul G.

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

  4. Petrie, Ichiko D.

    1. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017
      Jingjing Yu, Ichiko D. Petrie, René H. Levy and Isabelle Ragueneau-Majlessi
      Drug Metabolism and Disposition February 2019, 47 (2) 135-144; DOI: https://doi.org/10.1124/dmd.118.084905

  5. Podoll, Terry

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

Q

  1. Qiu, Nahong

    1. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
      Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt and Stephen Fowler
      Drug Metabolism and Disposition February 2019, 47 (2) 124-134; DOI: https://doi.org/10.1124/dmd.118.084301

R

  1. Ragueneau-Majlessi, Isabelle

    1. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017
      Jingjing Yu, Ichiko D. Petrie, René H. Levy and Isabelle Ragueneau-Majlessi
      Drug Metabolism and Disposition February 2019, 47 (2) 135-144; DOI: https://doi.org/10.1124/dmd.118.084905

  2. Renner, Matthew

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

  3. Roth, Sharin E.

    1. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
      James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer
      Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

  4. Rysz, Marta

    1. Serotonin Receptors of 5-HT2 Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone–Releasing Hormone/Growth Hormone Hormonal Pathway
      Ewa Bromek, Marta Rysz, Anna Haduch and Władysława A. Daniel
      Drug Metabolism and Disposition February 2019, 47 (2) 80-85; DOI: https://doi.org/10.1124/dmd.118.083808

S

  1. Sanghvi, Mitesh

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

  2. Scammells, Peter J.

    1. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives
      Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells and Richard Callaghan
      Drug Metabolism and Disposition February 2019, 47 (2) 164-172; DOI: https://doi.org/10.1124/dmd.118.083188

  3. Schmidt, Stephan

    1. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry
      Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt and Stephen Fowler
      Drug Metabolism and Disposition February 2019, 47 (2) 124-134; DOI: https://doi.org/10.1124/dmd.118.084301

  4. Shang, Xuyang

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  5. Shen, Zancong

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

  6. Shimizu, Hidetoshi

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

  7. Shoieb, Sherif M.

    1. Identification of 19-(S/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity
      Sherif M. Shoieb, Ahmed A. El-Sherbeni and Ayman O. S. El-Kadi
      Drug Metabolism and Disposition February 2019, 47 (2) 67-70; DOI: https://doi.org/10.1124/dmd.118.084657

  8. Slatter, J. Greg

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

  9. Sugiyama, Yuichi

    1. Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the “Albumin-Mediated” Hepatic Uptake Mechanism on the Basis of the “Facilitated-Dissociation Model”
      Soo-Jin Kim, Kyeong-Ryoon Lee, Seiji Miyauchi and Yuichi Sugiyama
      Drug Metabolism and Disposition February 2019, 47 (2) 94-103; DOI: https://doi.org/10.1124/dmd.118.083733

  10. Sun, Hao

    1. Open Access
      Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
      Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
      Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459

T

  1. Tian, Yuan

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

W

  1. Wang, Xin

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  2. Wilson, David M.

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

Y

  1. Yamazaki, Hiroshi

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

  2. Yang, Chun

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549

  3. Yoshida, Kosuke

    1. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
      Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru and Hiroshi Yamazaki
      Drug Metabolism and Disposition February 2019, 47 (2) 114-123; DOI: https://doi.org/10.1124/dmd.118.083642

  4. Yu, Jingjing

    1. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017
      Jingjing Yu, Ichiko D. Petrie, René H. Levy and Isabelle Ragueneau-Majlessi
      Drug Metabolism and Disposition February 2019, 47 (2) 135-144; DOI: https://doi.org/10.1124/dmd.118.084905

Z

  1. Zhang, Jingtao

    1. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation
      Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha and Andrew D. Patterson
      Drug Metabolism and Disposition February 2019, 47 (2) 86-93; DOI: https://doi.org/10.1124/dmd.118.083691

  2. Zhang, Yuanjin

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  3. Zhao, Junfang

    1. Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model
      Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu and Xin Wang
      Drug Metabolism and Disposition February 2019, 47 (2) 71-79; DOI: https://doi.org/10.1124/dmd.118.084277

  4. Zhou, Dongmei

    1. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers
      Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet and Caroline A. Lee
      Drug Metabolism and Disposition February 2019, 47 (2) 104-113; DOI: https://doi.org/10.1124/dmd.118.080549
Back to top

In this issue